Menu
Changing the Standard of Care for Fibroid Treatment and Fertility
Over 5.9% of women (226 million) have Uterine Fibroids world wide
70%-80%
Of women will develop uterine fibroid by the age of 50
20%-30%
Of women with fibroids are symptomatic
>70%
Of women with fibroids are on therapeutic plan
70%-75%
Of surgeries performed in US are hysterectomies
Symptoms
Menstrual
cramps and pain
Heavy menstrual
bleeding & anemia
Problems with
fertility or pregnancy
Bladder or bowel
symptoms
Uterine Fibroids are benign muscle tumors
Fibroids are classified by their size, shape and location
Myomectomy is The Golden Standard of Care for Uterine Preservation and Future Pregnancy Option.
Minimally Invasive or Laparoscopic Myomectomy Was First Described in the Late 1970’s
It is a Difficult Technique which has not Developed since the early 1990’s
Pressure Induced Fibroid Ischemia
The Empress system is intended to treat symptomatic uterine fibroids, in a laparoscopic procedure, by inducing fibroid tissue ischemia.
Sutures wrapped around the fibroid increases the intra-tumoral pressure which leads to fibroid Ischemia – blockage of intra- and peri-fibroid blood flow and, eventually, necrosis of the fibroid tissue.
Play Video
EMPRESS System Ease-of-Use Features
Simple Steps Battery Operated
Semi-Automated Advancement
Controlled Suture Technique
Guided Needle Path
Hand-held Untethered
No Thermal Energy
Published in Reproductive Sciences August 2022
Results from our First In Man Study Demonstrated Safety and Feasibility Of the Empress Procedure
Follow this link for the full article
First In Human Feasibility Study Summary
21 uterine fibroids were treated in 16 symptomatic pre-menopausal black women. Pelvic magnetic resonance imaging (MRI) was performed before the procedure, and at 1, 3, 6, and 12 months.
Results suggest the device is safe and can be effective for its intended purpose
36.3% treated fibroid volume reduction @ 3 months (p=.002)
60.4% treated fibroid volume reduction @ 12 months (p=.008)
100% procedural Success
Patients reported improvements in Energy/Mood, Control, and Sexual Function
Zero Adverse Events
Short Surgery Time
Positive Safety Profile
Improved Quality of Life at 3 months
Case Study
Before Empress Treatment
Fibroid Volume = 46cm3
0
%
Fibroid Volume Decrease
After 1 Year
Fibroid Volume = 8.6cm3
Empress is a technology company changing the standard of care for women with uterine fibroids
Who we are
Empress Medical is changing the standard of care for fibroid treatment – one of the highest prevalence painful conditions amongst women especially black and ethnic women. Incorporated in Delaware, United States in 2019, our team is international and preparing rapidly to enter a pivotal clinical phase in the US
What we do
We are focused on changing the standard of care for women worldwide and reducing the number of hysterectomies by introducing an easy-to-use laparoscopic technology designed for gynecologists operating in average settings, making it accessible to more underserved women, and delivering on the promise to offer a broader base of women a safe uterus preserving fibroid treatment option and preserving fertility
Why we do it
We are on a mission to reduce hysterectomies and give women with Uterine Fibroids a safe uterine preserving treatment option. When we succeed, more women with fibroids will be empowered to make better decisions about their treatment choice for preserving their uterus and future pregnancy options
BOARD OF DIRECTORS
Michael Tal, M.D
Empress’ Founder & Chairman
Interventional Radiologist
Former Associate Clinical Professor of Radiology at Yale University School of Medicine, US
Travis Sessions
Biomerics CEO
Managing Partner of Med Venture Holdings
Keren Leshem
OCON Therapeutics CEO
Aspivix BOD
CLINICAL ADVISORY
Kevin Stepp, M.D
Head of Advisory Board
FACOG, Female Pelvic Medicine and Reconstructive Surgery, Urogynecology
Ran Keidar, M.D
Advisory Board Member
OBGYN Surgeon, Specializing in advanced Endoscopy
MANAGEMENT TEAM
Angela Dotson
CEO
A seasoned executive with over 20 years of experience in the medical device space. The majority of her career has been working within the med tech start-up space in various sales roles where she has helped deliver on successful exits
Yuval Yona
VP R&D
Deep technical experience and background in development and production of medical devices
Hila Ravid
QA/RA Manager
Vast experience in regulation and certification of medical devices
Sigal Shachar
CFO
Over 15 years as a CFO in startups and corporations
Would you like to know more?
contact us
All rights reserved